Media Release

LASA SUPERGENERICS LIMITED
Registered Office: C-105, MIDC, Mahad, Maharashtra, 402301

Lasa Supergenerics Limited announces Q3 & 9MFY20 results

Mumbai, 10th February 2020: Lasa Supergenerics Limited, a vertically integrated group spanning the entire animal and human healthcare value chain has announced its financial results for the third quarter and nine months ended on December 31st, 2019.

Q3FY20 performance overview compared with Q3FY19

- Revenues from operations stood at Rs. 39.29 crore
- EBITDA of Rs. 8.16 crore; q-o-q growth of 8.7%
  - EBITDA margins at 20.77%
- PAT stood at Rs. 2.57 crore; PAT margin of 6.55%
- EPS for Q3FY20 stood at Rs. 0.89, as compared to Rs. (2.31) for Q3FY19

9MFY20 performance overview

- Revenues from operations stood at Rs. 118.69 cr
- EBITDA of Rs. 20.72 crore; y-o-y growth of 157.7%
  - EBITDA margins at 17.46%
- PAT stood at Rs. 1.06 crore; PAT margin of 0.89%
- EPS for 9MFY20 stood at Rs. 0.42, as compared to Rs. (4.47) for 9MFY19
For quarter ended December 31st, 2019

Total Income for the quarter ended December 31st, 2019 (Q3FY20) at Rs. 39.29 crore.

The Company reported Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) of Rs. 8.16 crore in Q3FY20, as against Rs 7.51 crore in Q2FY20; up 8.7%. The Company’s EBITDA margin improved from 18.58% in Q3FY19 to 20.77% in Q3FY20.

The Company reported a healthy PAT margin of 6.55% and PAT stood at Rs. 2.57 crore for Q3FY20, as compared to a loss of Rs. 5.28 crore in the corresponding quarter of last fiscal.

Standalone: Earnings per share (EPS for the quarter ended Q3FY20 stood at Rs. 0.89 as compared to Rs. -0.20 in Q2FY20

For nine months ended December 31st, 2019

Total Income for the 9MFY20 ended December 31st, 2019 at Rs. 118.69 crore. The Company reported Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) of Rs. 20.72 crore in 9MFY20, as against Rs 8.04 crore in 9MFY19; up 157.7%. The Company’s EBITDA margin improved from 6.30% in 9MFY19 to 17.46% in 9MFY20.

The Company reported a PAT of Rs. 1.05 crore for 9MFY20, as compared to a loss of Rs. 10.23 crore in the corresponding period last fiscal. The Company’s 9MFY20 PAT margin stood at a robust 0.89%, as against -8.01% in 9MFY19.

Commenting on the performance, Dr. Omkar Herlekar, Chairman– Lasa Supergenerics Limited, said “The Company is making progress considering the tough market conditions. Our collective efforts to reduce the finance costs and bring down the working capital cycle is visible and will be a sustained exercise. Rs 36.40 crores from our borrowings have been drastically retired from the corresponding period last fiscal; working capital cycle has dramatically improved from past. Benzimidazole Anthelmatics continues to be front product segment and we continue to see a strong growth potential in the animal healthcare market in India”
About Lasa Supergenerics Limited (www.lasalabs.com/; BSE: 540702; NSE: LASA)

Incorporated in 2011, Lasa Supergenerics Limited is a globally well trusted brand with high quality products, accepted by large companies across the globe. Our Company is the pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. The Company has its unit with state of art manufacturing facilities located at Mahad & Chiplun, Maharashtra with a total installed capacity of 4,300 MT. The Company has over 25% of APIs exported to counties like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea etc.

For more information contact:

Mr. Hitesh Wadhwani  
Lasa Supergenerics Ltd.  
Tel: 7798888147  
E-mail: hitesh@lasalabs.com

Mr. Gaurav Girdhar  
Concept Investor Relations  
Tel: +022 40558934  
M: +91 7798232425  
E-mail: gaurav.g@conceptpr.com

DISCLAIMER:

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Lasa Supergenerics Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.